Logo
x

Search

Subscribe Now

Dosing

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

  • April 30, 2021
J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

  • April 14, 2021
Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Le...

  • April 8, 2021
Roche Pauses Dosing of Tominersen in P-III GENERATION HD1 for Manifest Huntington's Disease

Roche Pauses Dosing of Tominersen in P-III GENERATION HD1 for Manifest Huntington's Disease

  • March 23, 2021
Pfizer Reports the First Patients Dosing of PF-06939926 in P-III CIFFREO Study for DMD

Pfizer Reports the First Patients Dosing of PF-06939926 in P-III CIFFREO Study for DMD

  • January 8, 2021
Formycon and Bioeq Report First Patients Dosing in P-III Study of FYB202 (biosimilar- ustekinumab)

Formycon and Bioeq Report First Patients Dosing in P-III Study of FYB202 (biosimilar- ustekinumab)

  • November 9, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.